Results

1–10 of 23 results for Faricimab

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Faricimab Response is Associated With Intraocular Pressure Lowering in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Tamara L Lenis, MD, PhD
Annual Meeting Talks
2024
Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Aude Ambresin, MD, PD
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024
12-Month Real-World Clinical and Anatomic Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022